Received Mar 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
medication error (unintentional)/an inappropriate use (unknown intention) due to patient receiving a second dose of MENQUADFI before the 8 week interval with no reported adverse event; Initial information received on 11-Mar-2026 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves an unknown age female patient who experienced medication error (unintentional)/an inappropriate use (unknown intention) due receiving a second dose of meningococcal A-C-Y-W135 (T conj) vaccine [MENQUADFI] before the 8 week interval with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s), family history were not provided. On 10-Dec-2025, the patient received an unknown dose of meningococcal A-C-Y-W135 (T conj) vaccine Solution for Injection (strength and expiry date unknown) via unknown route for unknown administration site for prophylactic vaccination. On 16-Dec-2025, the patient received second dose of meningococcal A-C-Y-W135 (T conj) vaccine Solution for Injection (strength and expiry date unknown) via unknown route for unknown administration site for prophylactic vaccination [immunisation] before the 8 week interval with no reported adverse event (inappropriate schedule of product administration) (Latency Same day). Information regarding batch number corresponding to the one at time of event occurrence is requested. Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error. ================================================================================
Comments: NONE